Table Info

Table 3.

Comparison of global 5-mC (%) between different categories of hyperprolactinemia cases and controls

Group (n)	5-mC (%), mean ± SD (range)	P value
Controls (65)	2.82 ± 1.40 (< 0.2–6.74)	NA
Hyperprolactinemia patients (83)	4.98 ± 2.68 (< 0.2–15.98)	< 0.0001^**
Drug-induced (37)	3.59 ± 1.91 (< 0.2–7.38)	0.0216^*
Idiopathic (28)	5.94 ± 2.83 (0.63–15.98)	< 0.0001^**
Pituitary adenoma (18)	6.34 ± 2.44 (1.8–11.41)	< 0.0001^**
Macroprolactinemia (20)	5.47 ± 3.5 (< 0.2–15.98)	< 0.0001^**
True hyperprolactinemia (63)	4.87 ± 2.33 (0.74–8.4)	< 0.0001^**

^* P < 0.05; ^** P < 0.0001; NA: not applicable

Declarations

Author contributions

AKK: Data curation, Formal analysis, Investigation, Software, Validation, Visualization, Writing—original draft, Writing—review & editing. AH: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing—review & editing. MJ: Methodology, Project administration, Resources, Supervision, Validation. JBS: Resources, Supervision, Validation. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Ethical clearance for the study was obtained from the Institute Ethics Committee, AIIMS, New Delhi, India (IESC/T-63/21.01.2015, RT-39/01.04.2015). All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional ethical committee. The study complies with the Declaration of Helsinki.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Informed consent to publication was obtained from relevant participants.

Availability of data and materials

Requests for accessing the datasets should be directed to [Amanpreet Kaur Kalsi, kalsi.amanpreetkaur@gmail.com].

Funding

This work was supported by the Department of Reproductive Biology, AIIMS. AKK was supported by the Council of Scientific & Industrial Research-University Grants Commission (CSIR-UGC) fellowship [23/06/2013(i)EU-V]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Grayson DR. Special issue introduction: role of epigenetic gene regulation in brain function. Genes (Basel). 2017;8:181. [DOI] [PubMed] [PMC]

Wen L, Li X, Yan L, Tan Y, Li R, Zhao Y, et al. Whole-genome analysis of 5-hydroxymethylcytosine and 5-methylcytosine at base resolution in the human brain. Genome Biol. 2014;15:R49. [DOI] [PubMed] [PMC]

Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13:484–92. [DOI] [PubMed]

McCarthy MM, Nugent BM. Epigenetic contributions to hormonally-mediated sexual differentiation of the brain. J Neuroendocrinol. 2013;25:1133–40. [DOI] [PubMed] [PMC]

Nugent BM, Schwarz JM, McCarthy MM. Hormonally mediated epigenetic changes to steroid receptors in the developing brain: implications for sexual differentiation. Horm Behav. 2011;59:338–44. [DOI] [PubMed] [PMC]

Rao ML, Gross G, Strebel B, Halaris A, Huber G, Bräunig P, et al. Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry. 1994;35:151–63. [DOI] [PubMed]

Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22:724–63. [DOI] [PubMed]

Liu JC, Baker RE, Chow W, Sun CK, Elsholtz HP. Epigenetic mechanisms in the dopamine D2 receptor-dependent inhibition of the prolactin gene. Mol Endocrinol. 2005;19:1904–17. [DOI] [PubMed]

Kononen J, Honkaniemi J, Gustafsson JA, Pelto-Huikko M. Glucocorticoid receptor colocalization with pituitary hormones in the rat pituitary gland. Mol Cell Endocrinol. 1993;93:97–103. [DOI] [PubMed]

10.

Elsholtz HP, Lew AM, Albert PR, Sundmark VC. Inhibitory control of prolactin and Pit-1 gene promoters by dopamine. Dual signaling pathways required for D2 receptor-regulated expression of the prolactin gene. J Biol Chem. 1991;266:22919–25. [PubMed]

11.

McChesney R, Sealfon SC, Tsutsumi M, Dong KW, Roberts JL, Bancroft C. Either isoform of the dopamine D₂ receptor can mediate dopaminergic repression of the rat prolactin promoter. Mol Cell Endocrinol. 1991;79:R1–7. [DOI] [PubMed]

12.

Camper SA, Yao YA, Rottman FM. Hormonal regulation of the bovine prolactin promoter in rat pituitary tumor cells. J Biol Chem. 1985;260:12246–51. [PubMed]

13.

Liu YF, Jakobs KH, Rasenick MM, Albert PR. G protein specificity in receptor-effector coupling. Analysis of the roles of G0 and Gi2 in GH4C1 pituitary cells. J Biol Chem. 1994;269:13880–6. [PubMed]

14.

Day RN, Walder JA, Maurer RA. A protein kinase inhibitor gene reduces both basal and multihormone-stimulated prolactin gene transcription. J Biol Chem. 1989;264:431–6. [PubMed]

15.

Lew AM, Yao H, Elsholtz HP. G_iα2- and G_oα- mediated signaling in the Pit-1-dependent inhibition of the prolactin gene promoter. Control of transcription by dopamine D2 receptors. J Biol Chem. 1994;269:12007–13. [PubMed]

16.

Gangisetty O, Wynne O, Jabbar S, Nasello C, Sarkar DK. Fetal alcohol exposure reduces dopamine receptor D2 and increases pituitary weight and prolactin production via epigenetic mechanisms. PLoS One. 2015;10:e0140699. [DOI] [PubMed] [PMC]

17.

Ajmal A, Joffe H, Nachtigall LB. Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55:29–36. [DOI] [PubMed]

18.

Alosaimi FD, Fallata EO, Abalhassan M, Alhabbad A, Alzain N, Alhaddad B, et al. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int J Psychiatry Clin Pract. 2018;22:274–81. [DOI] [PubMed]

19.

Melgar V, Espinosa E, Sosa E, Rangel MJ, Cuenca D, Ramírez C, et al. Current diagnosis and treatment of hyperprolactinemia. Rev Med Inst Mex Seguro Soc. 2016;54:111–21. Spanish. [PubMed]

20.

Pałubska S, Adamiak-Godlewska A, Winkler I, Romanek-Piva K, Rechberger T, Gogacz M. Hyperprolactinaemia–a problem in patients from the reproductive period to the menopause. Prz Menopauzalny. 2017;16:1–7. [DOI] [PubMed] [PMC]

21.

Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–63. [DOI] [PubMed]

22.

Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, Holley S, et al. Isolation and characterization of a novel pituitary tumor apoptosis gene. Mol Endocrinol. 2004;18:1827–39. [DOI] [PubMed]

23.

Bahar A, Bicknell JE, Simpson DJ, Clayton RN, Farrell WE. Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation. Oncogene. 2004;23:936–44. [DOI] [PubMed]

24.

Simpson DJ, Bicknell JE, McNicol AM, Clayton RN, Farrell WE. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer. 1999;24:328–36. [DOI] [PubMed]

25.

Dudley KJ, Revill K, Whitby P, Clayton RN, Farrell WE. Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors. Mol Cancer Res. 2008;6:1567–74. [DOI] [PubMed]

26.

Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics—a review. Hum Psychopharmacol. 2010;25:281–97. [DOI] [PubMed]

27.

Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, et al. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med. 2013;369:2012–20. [DOI] [PubMed] [PMC]

28.

Davis JR. Prolactin and reproductive medicine. Curr Opin Obstet Gynecol. 2004;16:331–7. [DOI] [PubMed]

29.

Kalsi AK, Halder A, Jain M, Chaturvedi PK, Sharma JB. Prevalence and reproductive manifestations of macroprolactinemia. Endocrine. 2019;63:332–40. [DOI] [PubMed]

30.

Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215. [DOI] [PubMed] [PMC]

31.

Melas PA, Rogdaki M, Ösby U, Schalling M, Lavebratt C, Ekström TJ. Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset. FASEB J. 2012;26:2712–8. [DOI] [PubMed]

32.

Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7. [DOI] [PubMed] [PMC]

33.

Singh SM, Murphy B, O’Reilly R. Epigenetic contributors to the discordance of monozygotic twins. Clin Genet. 2002;62:97–103. [DOI] [PubMed]

34.

Melka MG, Laufer BI, McDonald P, Castellani CA, Rajakumar N, O’Reilly R, et al. The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum. Clin Epigenetics. 2014;6:1. [DOI] [PubMed] [PMC]

35.

Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades A, Kane F, et al. Disease-associated epigenetic changes in monozygotic twins discordant for schizophrenia and bipolar disorder. Hum Mol Genet. 2011;20:4786–96. [DOI] [PubMed] [PMC]

36.

Wockner LF, Noble EP, Lawford BR, Young RM, Morris CP, Whitehall VL, et al. Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Transl Psychiatry. 2014;4:e339. [DOI] [PubMed] [PMC]

37.

Kinoshita M, Numata S, Tajima A, Shimodera S, Ono S, Imamura A, et al. DNA methylation signatures of peripheral leukocytes in schizophrenia. Neuromolecular Med. 2013;15:95–101. [DOI] [PubMed]

38.

Bönsch D, Wunschel M, Lenz B, Janssen G, Weisbrod M, Sauer H. Methylation matters? Decreased methylation status of genomic DNA in the blood of schizophrenic twins. Psychiatry Res. 2012;198:533–7. [DOI] [PubMed]

39.

Shimabukuro M, Jinno Y, Fuke C, Okazaki Y. Haloperidol treatment induces tissue- and sex-specific changes in DNA methylation: a control study using rats. Behav Brain Funct. 2006;2:37. [DOI] [PubMed] [PMC]

40.

Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci USA. 2008;105:13614–9. [DOI] [PubMed] [PMC]

41.

Mill J, Tang T, Kaminsky Z, Khare T, Yazdanpanah S, Bouchard L, et al. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet. 2008;82:696–711. [DOI] [PubMed] [PMC]

42.

Tremolizzo L, Doueiri MS, Dong E, Grayson DR, Davis J, Pinna G, et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry. 2005;57:500-9. [DOI] [PubMed]

43.

Byrne EM, Carrillo-Roa T, Henders AK, Bowdler L, McRae AF, Heath AC, et al. Monozygotic twins affected with major depressive disorder have greater variance in methylation than their unaffected co-twin. Transl Psychiatry. 2013;3:e269. [DOI] [PubMed] [PMC]

44.

Coiro V, Davoli C, Volpi R, Sorini E, Voltini E, Rossi G, et al. The gabaergic control of prolactin release is not affected by insulin-dependent diabetes mellitus: evidence from studies with sodium valproate. Acta Diabetol Lat. 1986;23:51–5. [DOI] [PubMed]

45.

Noh JS, Sharma RP, Veldic M, Salvacion AA, Jia X, Chen Y, et al. DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proc Natl Acad Sci USA. 2005;102:1749–54. [DOI] [PubMed] [PMC]

46.

Dong E, Agis-Balboa RC, Simonini MV, Grayson DR, Costa E, Guidotti A. Reelin and glutamic acid decarboxylase67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc Natl Acad Sci USA. 2005;102:12578–83. [DOI] [PubMed] [PMC]

47.

Dong E, Guidotti A, Grayson DR, Costa E. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci USA. 2007;104:4676–81. [DOI] [PubMed] [PMC]

48.

Muccioli G, Di Carlo R. S-adenosyl-L-methionine restores prolactin receptors in the aged rabbit brain. Eur J Pharmacol. 1989;166:223–30. [DOI] [PubMed]

49.

Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734–41. [DOI] [PubMed]

50.

Sharma RP, Rosen C, Kartan S, Guidotti A, Costa E, Grayson DR, et al. Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population. Schizophr Res. 2006;88:227–31. [DOI] [PubMed]

51.

Sharma RP, Grayson DR, Gavin DP. Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection. Schizophr Res. 2008;98:111–7. [DOI] [PubMed] [PMC]

52.

Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci. 2012;15:1245–54. [DOI] [PubMed] [PMC]

53.

Weaver IC, Cervoni N, Champagne FA, D’Alessio AC, Sharma S, Seckl JR, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7:847–54. [DOI] [PubMed]

54.

Borba VV, Zandman-Goddard G, Shoenfeld Y. Prolactin and autoimmunity. Front Immunol. 2018;9:73. [DOI] [PubMed] [PMC]

55.

Hassan MI, Kumar V, Singh TP, Yadav S. Purification and characterization of zinc α2-glycoprotein-prolactin inducible protein complex from human seminal plasma. J Sep Sci. 2008;31:2318–24. [DOI] [PubMed]

56.

Bjorkman PJ, Parham P. Structure, function, and diversity of class I major histocompatibility complex molecules. Annu Rev Biochem. 1990;59:253–88. [DOI] [PubMed]

57.

Hassan I, Ahmad F. Structural diversity of class I MHC-like molecules and its implications in binding specificities. Adv Protein Chem Struct Biol. 2011;83:223–70. [DOI] [PubMed]

58.

Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol. 1995;13:587–622. [DOI] [PubMed]

59.

Davies CJ, Eldridge JA, Fisher PJ, Schlafer DH. Evidence for expression of both classical and non-classical major histocompatibility complex class I genes in bovine trophoblast cells. Am J Reprod Immunol. 2006;55:188–200. [DOI] [PubMed]

60.

Rapacz-Leonard A, Dąbrowska M, Janowski T. Major histocompatibility complex I mediates immunological tolerance of the trophoblast during pregnancy and may mediate rejection during parturition. Mediators Inflamm. 2014;2014:579279. [DOI] [PubMed] [PMC]

61.

King A, Boocock C, Sharkey AM, Gardner L, Beretta A, Siccardi AG, et al. Evidence for the expression of HLAA-C class I mRNA and protein by human first trimester trophoblast. J Immunol. 1996;156:2068–76. [PubMed]

62.

Bainbridge DR. Evolution of mammalian pregnancy in the presence of the maternal immune system. Rev Reprod. 2000;5:67–74. [DOI] [PubMed]

63.

Trowsdale J, Moffett A. NK receptor interactions with MHC class I molecules in pregnancy. Semin Immunol. 2008;20:317–20. [DOI] [PubMed]

64.

Hviid TV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Update. 2006;12:209–32. [DOI] [PubMed]

65.

Ishitani A, Sageshima N, Lee N, Dorofeeva N, Hatake K, Marquardt H, et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E, F, and G in maternal-placental immune recognition. J Immunol. 2003;171:1376–84. [DOI] [PubMed]

66.

Robinson DP, Klein SL. Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. Horm Behav. 2012;62:263–71. [DOI] [PubMed] [PMC]

67.

Mori M, Bogdan A, Balassa T, Csabai T, Szekeres-Bartho J. The decidua—the maternal bed embracing the embryo—maintains the pregnancy. Semin Immunopathol. 2016;38:635–49. [DOI] [PubMed] [PMC]

68.

Haynes RL, Zheng T, Nicchitta CV. Structure and folding of nascent polypeptide chains during protein translocation in the endoplasmic reticulum. J Biol Chem. 1997;272:17126–33. [DOI] [PubMed]

69.

Tougard C, Louvard D, Picart R, Tixier-Vidal A. The rough endoplasmic reticulum and the Golgi apparatus visualized using specific antibodies in normal and tumoral prolactin cells in culture. J Cell Biol. 1983;96:1197–207. [DOI] [PubMed] [PMC]

70.

Walter P, Blobel G. Translocation of proteins across the endoplasmic reticulum. II. Signal recognition protein (SRP) mediates the selective binding to microsomal membranes of in-vitro-assembled polysomes synthesizing secretory protein. J Cell Biol. 1981;91:551–6. [DOI] [PubMed] [PMC]

71.

Lavialle F, Rainteau D, Massey-Harroche D, Metz F. Establishment of plasma membrane polarity in mammary epithelial cells correlates with changes in prolactin trafficking and in annexin VI recruitment to membranes. Biochim Biophys Acta. 2000;1464:83–94. [DOI] [PubMed]

72.

Fang X, Chen C, Cai J, Xiang E, Li J, Chen P. Genome-wide methylation study of whole blood cells DNA in men with congenital hypopituitarism disease. Int J Mol Med. 2019;43:155–66. [DOI] [PubMed] [PMC]

73.

Duong CV, Emes RD, Wessely F, Yacqub-Usman K, Clayton RN, Farrell WE. Quantitative, genome-wide analysis of the DNA methylome in sporadic pituitary adenomas. Endocr Relat Cancer. 2012;19:805–16. [DOI] [PubMed]

74.

Li S, Zhu D, Duan H, Ren A, Glintborg D, Andersen M, et al. Differential DNA methylation patterns of polycystic ovarian syndrome in whole blood of Chinese women. Oncotarget. 2017;8:20656–66. [DOI] [PubMed] [PMC]

75.

Díaz L, Muñoz MD, González L, Lira-Albarrán S, Larrea F, Méndez I. Prolactin in the immune system. In: Nagy GM, Toth BE, editors. Prolactin. IntechOpen; 2013. pp. 53–82. [DOI]

76.

Szosland K, Pawlowicz P, Lewiński A. Prolactin secretion in polycystic ovary syndrome (PCOS). Neuro Endocrinol Lett. 2015;36:53–8. [PubMed]